Claritas Rx is a frontrunner in using data to produce better outcomes in patient care and higher profits to bio-pharma families. From being simply channel data consultancy, it has grown to become a top-level source for patient-level data integration and analytics-that is an advantage bio-pharma manufacturer’s need in a rapid change market environment.

Enabling Market Access Teams with Real-Time Insights

Specialty pharmaceuticals require timely interventions to retain patients and ensure the best treatment outcomes. thus Claritas Rx provides a market access team with real-time actionable insights from a variety of sources: payer dispenses data, ICD-10 codes, pharmacy notes, and so on. This is a comprehensive view of patient journeys, allowing pharmaceutical brands to readily know when a patient might discontinue treatment, hence wise intervention before the patient disappears.

The power of patient behavior and market trend comprehension is what drives Claritas Rx's analytics to enable bio-pharma companies to become data-agile for optimum clinical interventions directed toward more effective engagement with patients to enhance therapy adherence.                  

Gaining Competitive Advantage with Competitive Market Analysis

Comparative market analysis or competition analysis is one of those many aspects that best suit the needs of Claritas Rx that makes brands gain a competitive advantage. The comparative market analysis shows how a particular buy performs against competitors in the market. It can thus allow a particular company to assess where they lie in the marketplace and identify new opportunities or understand why patients may prefer competing therapies to their products.

Market access teams can modify course on how they carry their activities, remaining competitive and ahead of the game when it comes to patient engagement and marketing of brands.

Transforming System in Data Aggregation for Better Decision Making

Claritas Rx is the best at data aggregation or the pulling of multifarious data from sources in order to effectively construct a comprehensive image or field of patient behavior. Data gathering here does not merely involve claims-based data collection that many conventional data sources depend on. It involves linking data from various channels, hence a deeper understanding of what and how patients experience their health. This robust data aggregation allows market access teams to better and rapidly decide about their programs and strategies.

Claritas Rx streamlines data collection, validation, and curation processes to provide clean, reliable, and current data to improve the decision-making process. It could also allow bio-pharma to focus on program performance rather than detailing the management of raw data.

Specific Insights for Attributed Patient Care and Brand Performance

The success of a specialty pharmaceutical brand hinges on optimizing patient outcomes and business performance. Claritas Rx’s platform delivers targeted insights tailored to each organization’s specific needs, whether assessing treatment efficacy or enhancing market access strategies. By ensuring decisions are based on clear, actionable data and providing comprehensive insights across the patient experience, Claritas Rx enables bio-pharma companies to continuously refine their approaches, ensuring optimal patient outcomes.

Leading the Way in Data-Driven Patient Care

Claritas Rx is standard-setting in establishing data-driven decision making for the specialty pharmaceutical industry. It is an innovative platform through which biopharma can realize the value of patient-level data that brings insight not only into patient outcomes but also optimizes strategies for treatment and enhances competitive positioning. So, as the industry changes, so will Claritas Rx, a partner that can help these entities keep a step ahead of the curve in the changing landscape of healthcare.

About the Leader

Mike Fitzgibbons, Founder & Chief Executive Officer of Claritas Rx, has played a number of roles in marketing and managed care at Genentech. His work spanned life cycle planning, commercial launch preparation, pricing strategy and distribution strategy. The combination of Mike’s experience in Genentech’s Managed Care and Customer Operations organization and his time on the Avastin Marketing Team led to Claritas Rx’s focus on leveraging patient-level data to tangibly improve how companies understand product performance and support patients through their treatment journey. Prior to Genentech, Mike was an equity research analyst at Morgan Stanley covering pharmaceutical services, drug distribution and healthcare information technology. He holds the Chartered Financial Analyst (CFA) designation.

“Claritas Rx transforms data into strategic advantage, fostering patient-centric solutions, informed decision-making, and unparalleled impact in the dynamic realm of biopharmaceutical analytics.”